Collectively, these results suggest that long-term treatment of AML cells with HMAs, the bioactive metabolites of which are fully (DAC) or only in part (AZA) SAMHD1-dependent, results in SAMHD1-overexpressing leukemic cells. The gene discussed is SAMHD1; the disease is acute myeloid leukemia.